Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | HTR2C | P28335 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HTR1D | P28221 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675799 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL2778860 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL7460028 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL6631651 | 0.83 | KDM4E (0.70) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL2783986 | 0.83 | HTR6 (0.67) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL13533314 | 0.82 | HTR6 (0.63) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| Water SCHEMBL10867618 | 0.82 | HTR6 (0.70) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL4880407 | 0.81 | HTR6 (1.00) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL6631360 | 0.80 | HTR6 (0.60) | HTR6KDM4EALDH1A1HSD17B10HTR2C | |
| SCHEMBL12648562 | 0.80 | KDM4E (0.62) | HTR6KDM4EALDH1A1HSD17B10HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7635696-B2 | Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-1819713-B1 | ISOXAZOLINE-INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC AND ANXIOLYTIC A IVITY | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080113988-A1 | Isoxazoline-Indole Derivatives With an Improved Antipsychotic and Anxiolytic Activity | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| CN-1093125-C | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-23 | — | — | CN | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| CN-1250445-A | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-12 | — | — | CN | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| EP-0683166-B1 | 3-Indolylpiperidines | MERCK PATENT GMBH (DE) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
| US-5693655-A | 3-indolylpiperidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | disclosed |
| EP-0683166-A1 | 3-Indolylpiperidines | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | disclosed |
| US-5036075-A | Serotonin antagonists | RHONE-POULENC SANTE (FR) | 1991-07-30 | — | — | US | disclosed |
| US-5021420-A | Antiserotonine agents; central nervous system, gastroin-testinal and cardiovascular disorders | RHONE-POULENC SANTE (FR) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR6 1/4885KDM4E 3933/4885ALDH1A1 2581/4885 |
| US-20080113988-A1 | Isoxazoline-Indole Derivatives With an Improved Antipsychotic and Anxiolytic Activity | HTR3A, HTR2C, HTR5A | HTR6 95/4885KDM4E 3900/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.